Star Imaging and Path Lab Ltd (544482)
🎯 Key Takeaways
- Star Imaging and Path Lab Ltd appears to be in a mature, capital-light phase with stable governance and minimal external financing activity, as evidenced by consistent promoter holding and low institutional participation. The company operates in healthcare diagnostics but shows no signs of aggressive expansion or margin recovery, with financial metrics indicating stagnation in asset growth and persistent cash outflows.
- ⚠️ 1) Persistent negative operating cash flow with no clear path to improvement, raising concerns about sustainability of operations. 2) Low institutiona
📖 The Story
Star Imaging and Path Lab Ltd appears to be in a mature, capital-light phase with stable governance and minimal external financing activity, as evidenced by consistent promoter holding and low institutional participation. The company operates in healthcare diagnostics but shows no signs of aggressive expansion or margin recovery, with financial metrics indicating stagnation in asset growth and persistent cash outflows.
📰 What's Happening
The board recently convened to approve the 22nd AGM scheduled for 29 September 2026 via video conference, endorsing the FY2025-26 annual report and reappointing key auditors including Sheetal & Company and Mr. Suraj Verma as internal auditor. Ms. Neelam Ratra’s reappointment as director signals governance continuity, while the remote e-voting mechanism reflects shareholder engagement despite a largely passive investor base.
Source: Stock Announcements
🔮 Management Outlook & What's Next
Management has not provided forward guidance on revenue growth, margins, or strategic initiatives in the latest filings, focusing instead on procedural governance items like AGM logistics and auditor reappointments. The absence of strategic commentary or performance targets suggests limited near-term visibility on value creation beyond routine compliance and statutory obligations.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 14 | 17 | 17 |
| Reserves | 34 | 89 | 99 |
| Borrowings | 33 | 20 | 21 |
| Total Liabilities | 98 | 129 | 139 |
| Fixed Assets | 21 | 26 | 25 |
| Investments | 0 | 0 | 0 |
| Total Assets | 98 | 129 | 147 |
The balance sheet reveals a capital-efficient but stagnant structure: equity and reserves have risen modestly, while borrowings remain low and stable, indicating conservative capital allocation. There is no evidence of share buybacks, dividend announcements, or debt reduction, implying retained earnings are not being deployed for shareholder returns or aggressive reinvestment.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -6 |
| Investing | -4 |
| Financing | -0 |
| Net Cash Flow | -10 |
👥 Shareholding Pattern
| Category | Q4FY25 | Q2FY26 | Q4FY26 |
|---|---|---|---|
| Promoters | 100.0% | 71.9% | 71.9% |
| FII | 0.0% | 1.4% | 0.6% |
| DII | 0.0% | 9.3% | 6.1% |
| Public | 0.0% | 12.3% | 16.2% |
| # Shareholders | 7 | 779 | 773 |
Promoter holding remains stable at 71.92%, but FII and DII participation has declined from 1.37% and 9.33% in Q2FY26 to 0.61% and 6.14% in Q4FY26, respectively, suggesting institutional disinvestment. The drop from 100% promoter ownership in Q4FY25 to current levels reflects a structural shift toward broader, but shallow, public float and reduced institutional confidence.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.26 L Cr | 60.3 | 22.1% | 22.9% | 0.60 |
| MANIPALHOS | 98,259 | — | — | — | 1.25 |
| MAXHEALTH | 98,006 | 67.2 | 14.4% | 13.6% | 0.27 |
| FORTIS | 68,769 | 65.6 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 66,090 | 122.7 | 17.2% | 11.9% | 0.21 |
| NH | 39,605 | 48.2 | 13.7% | 18.0% | 1.07 |
| MEDANTA | 39,163 | 70.4 | 21.9% | 16.3% | 0.10 |
| LALPATHLAB | 31,910 | 45.9 | 29.6% | 21.8% | 0.00 |
| KIMS | 31,878 | 148.8 | 9.7% | 8.7% | 1.44 |
| POLYMED | 17,790 | 56.5 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Persistent negative operating cash flow with no clear path to improvement, raising concerns about sustainability of operations. 2) Low institutional and public shareholding with high promoter concentration increases vulnerability to governance risks and limited liquidity. 3) Absence of forward-looking guidance or strategic initiatives from management leaves growth prospects ambiguous and unvalidated.
📋 Recent Filings
-
🔴 annual report 1 September 2026Star Imaging and Path Lab Limited reported FY26 revenue of ₹88.5 crore, up 6% YoY, with EBITDA margin expanding to 37.5% and PAT margin reaching 21.8%...
-
🟡 Board Meeting 1 September 2026Star Imaging and Path Lab Ltd announced its 22nd AGM on September 29, 2025, held virtually via VC/OAVM with e-voting open from September 26 to 28, 202...
-
🔴 annual report 1 September 2026Star Imaging and Path Lab Ltd announced that its 22nd Annual General Meeting will be held on 29 September 2026 at 2 PM IST via video conference, with ...
-
🟡 Board Meeting 28 August 2026The board approved the 22nd AGM scheduled for 29 September 2026 via VC, set e-voting cut-off on 24 September and remote voting from 26 to 28 September...
-
🟡 Board Meeting 28 August 2026The board approved the 22nd AGM scheduled for 29 September 2026 via video conference, set e-voting cut-off on 24 September and remote voting from 26 t...
-
🟡 concall transcript 31 March 2026Star Imaging and Path Lab Limited reported FY26 revenue of INR88.5 crores, up 6% YoY, with EBITDA at INR33.2 crores (37.5% margin) and PAT at INR19.3 ...
🧠 Analyst's Read
The company exhibits characteristics of a dormant or dormant-turnaround candidate with stable but uninspiring financials and governance, lacking catalysts for re-rating; investors should monitor for any shift in strategic direction, margin improvement, or cash flow recovery in upcoming quarters.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd